Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$1.38 - $3.31 $318 - $764
-231 Reduced 0.82%
27,778 $38,000
Q2 2023

Aug 11, 2023

SELL
$2.33 - $6.84 $428,361 - $1.26 Million
-183,846 Reduced 86.78%
28,009 $84,000
Q1 2023

May 15, 2023

SELL
$3.46 - $7.98 $10,245 - $23,628
-2,961 Reduced 1.38%
211,855 $1.32 Million
Q4 2022

Feb 13, 2023

SELL
$5.26 - $12.19 $30,550 - $70,799
-5,808 Reduced 2.63%
214,816 $1.31 Million
Q3 2022

Nov 14, 2022

SELL
$9.86 - $15.76 $49,122 - $78,516
-4,982 Reduced 2.21%
220,624 $2.64 Million
Q2 2022

Aug 12, 2022

BUY
$7.43 - $13.0 $132,023 - $230,997
17,769 Added 8.55%
225,606 $2.85 Million
Q1 2022

May 13, 2022

SELL
$7.73 - $17.99 $44,061 - $102,542
-5,700 Reduced 2.67%
207,837 $2.34 Million
Q4 2021

Feb 08, 2022

BUY
$16.5 - $25.48 $36,036 - $55,648
2,184 Added 1.03%
213,537 $3.78 Million
Q3 2021

Nov 15, 2021

BUY
$17.81 - $24.87 $1.35 Million - $1.89 Million
75,840 Added 55.97%
211,353 $4.87 Million
Q2 2021

Aug 13, 2021

SELL
$22.19 - $31.55 $224,008 - $318,497
-10,095 Reduced 6.93%
135,513 $3.16 Million
Q1 2021

May 12, 2021

BUY
$26.99 - $40.0 $3.93 Million - $5.82 Million
145,608 New
145,608 $4.54 Million

Others Institutions Holding KNTE

About Kinnate Biopharma Inc.


  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.